ClinicalTrials.gg
WithdrawnNCT03988114proMONARCHUpdated Sep 6, 2019

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

A Phase 4 interventional study of Abemaciclib and Nonsteroidal Aromatase Inhibitor (NSAI) in Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Withdrawn at 119 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-06.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Strategic decision due to emerging new data for patients with HR+, HER2- metastatic breast cancer.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Enrollment
52nd of 55
0 · median 120
Started
2019
with 2 others
Phase 4
8 of 55
4 open now
Registered
17th of 55
by date
Lead sponsor
17 of 55
Eli Lilly and Company

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 52nd largest by enrollment, is one of 3 that started in 2019, is one of 8 in phase 4, and was the 17th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The reason for this study is to see if the drug abemaciclib in combination with nonsteroidal aromatase inhibitors (anastrozole or letrozole) is effective in participants with Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) advanced breast cancer that have certain disease characteristics.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have completed (neo) endocrine therapy and have cancer return after at least 12 months or have de novo cancer that has spread to other organs at diagnosis
  • Participants must have 1 or more of the following:

    • A high grade tumor in tissue
    • Negative progesterone receptor (PR) status
    • Have cancer that has spread to the liver
    • Have a treatment-free interval (TFI) \<36 months
  • Participants must have HR+, - breast cancer
  • Participants must have adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Participants must not have cancer that has spread to other organs that has severely affected their function
  • Participants must not have cancer that has spread to the brain that is unstable or untreated
  • Participants must not have received endocrine therapy in the setting
  • Participants must not have known active infection
  • Participants must not have received prior endocrine therapy and had disease return within 12 months from completion of treatment
  • Participants must not have received prior treatment with any cyclin-dependent kinase (CDK) 4 \& 6 inhibitor or everolimus
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Abemaciclib + NSAI

    Abemaciclib given orally and nonsteroidal aromatase inhibitor (NSAI) of physician's choice (anastrazole or letrozole) given orally.

    Drug: Abemaciclib · Drug: Nonsteroidal Aromatase Inhibitor (NSAI)

Interventions

  • Administered orally

    Also known as: LY2835219

  • DrugNonsteroidal Aromatase Inhibitor (NSAI)

    Letrozole administered orally or anastrozole administered orally (physician choice)

This study also gives Anastrozole. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS

    Time frame: Baseline to Progressive Disease or Death from Any Cause (Estimated up to 26 Months)

  2. Objective Response Rate (ORR): Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR)

    ORR

    Time frame: Baseline to Objective Disease Progression (Estimated up to 26 Months)

Secondary outcomes

  1. Duration of Response (DoR)

    DoR

    Time frame: Date of CR or PR to Date of Objective Disease Progression or Death from Any Cause (Estimated up to 26 Months)

  2. Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of CR, PR, or Stable Disease (SD)

    DCR

    Time frame: Baseline to Objective Disease Progression (Estimated up to 26 Months)

  3. Clinical Benefit Rate (CBR): Proportion of Participants with Best Overall Response of CR, PR, or SD with Duration of SD for at Least 6 Months

    CBR

    Time frame: Date of CR, PR or SD to 6 Months Post CR, PR or SD (Estimated up to 26 Months)

  4. Time to Response (TTR)

    TTR

    Time frame: Baseline to Date of CR or PR (Estimated up to 26 Months)

07

Study locations

119 sites
  • Southern Cancer Center, P.C.
    Daphne, Alabama 36526, United States
  • Arizona Oncology Associates, P.C.
    Tempe, Arizona 85284, United States
  • Compassionate Cancer Care Medical Group Inc
    Fountain Valley, California 92708, United States
  • California Cancer Associates Research and Excellence (cCARE)
    Fresno, California 93720, United States
  • Beaver Medical Group
    Highland, California 92346, United States
  • Pacific Cancer Care
    Monterey, California 93940, United States
  • St. Joseph Hospital
    Orange, California 92868, United States
  • Comprehensive Cancer Centers of the Desert
    Palm Springs, California 92262, United States
  • California Cancer Associates in Research and Excellence
    San Marcos, California 92069, United States
  • Cancer Center of Santa Barbara with Sansum Clinic
    Santa Barbara, California 93105, United States
  • UCLA Medical Center
    Torrance, California 90502, United States
  • Memorial Hospital
    Colorado Springs, Colorado 80909, United States
  • Rocky Mountain Cancer Center
    Lone Tree, Colorado 80124, United States
  • Medical Oncology Hematology Consultants, PA
    Newark, Delaware 19713, United States
  • BayCare Medical Group
    Clearwater, Florida 33756, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Woodlands Medical Specialists
    Pensacola, Florida 32503, United States
  • Cancer Specialists of North Florida -St Augustine
    Saint Augustine, Florida 32086, United States
  • Florida Cancer Specialists
    Saint Petersburg, Florida 33705, United States
  • Florida Cancer Specialists
    Tallahassee, Florida 32308, United States
  • Florida Cancer Specialists
    West Palm Beach, Florida 33401, United States
  • Cleveland Clinic of Florida
    Weston, Florida 33331, United States
  • Summit Cancer Care
    Savannah, Georgia 31404, United States
  • Ingalls Memorial Hospital
    Harvey, Illinois 60426, United States
  • Illinois Cancer Specialists-Niles
    Niles, Illinois 60714, United States
  • Community Health Network
    Indianapolis, Indiana 46219, United States
  • Central Maine Medical Center
    Lewiston, Maine 04240, United States
  • York Hospital
    York, Maine 03909, United States
  • HCA Midwest
    Kansas City, Missouri 64132, United States
  • Oncology Hematology West
    Omaha, Nebraska 68130, United States
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89052, United States
  • Valley Health System
    Paramus, New Jersey 07652, United States
  • Broome Oncology LLC
    Johnson City, New York 13790, United States
  • Abington Hematology Oncology Associates
    Horsham, Pennsylvania 19044, United States
  • Charleston Hematology Oncology Associates
    Charleston, South Carolina 29414, United States
  • Sarah Cannon Research Institute SCRI
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37203, United States
  • Texas Oncology - Abilene
    Abilene, Texas 79606, United States
  • Texas Oncology - Amarillo
    Amarillo, Texas 79106, United States
  • Texas Oncology-Arlington South
    Arlington, Texas 76014, United States
  • Texas Oncology Cancer Center
    Austin, Texas 78731, United States
  • Texas Oncology - Bedford
    Bedford, Texas 76022, United States
  • Texas Oncology P.A.
    Dallas, Texas 75203, United States
  • Texas Oncology - Medical City Dallas
    Dallas, Texas 75230, United States
  • Texas Oncology - Dallas Presbyterian Hospital
    Dallas, Texas 75231, United States
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Texas Oncology - Marnie McFadden Ward Cancer Center
    Dallas, Texas 77702, United States
  • Texas Oncology P.A.
    El Paso, Texas 79902, United States
  • Texas Oncology Flower Mound
    Flower Mound, Texas 75028, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Texas Oncology-Memorial City
    Houston, Texas 77024, United States
  • Renovatio Clinical
    Houston, Texas 77056, United States
  • Texas Oncology - McAllen
    McAllen, Texas 78503, United States
  • Texas Oncology-McKinney
    McKinney, Texas 75771, United States
  • Texas Oncology- Mesquite
    Mesquite, Texas 75150, United States
  • Texas Oncology - Midland Allison Cancer Center
    Midland, Texas 79701, United States
  • Texas Oncology - Paris
    Paris, Texas 75460, United States
  • Texas Oncology-Plano East
    Plano, Texas 75075, United States
  • Texas Oncology-Plano West
    Plano, Texas 75093, United States
  • Texas Oncology - San Antonio Medical Center
    San Antonio, Texas 78217, United States
  • Texas Oncology-Sherman
    Sherman, Texas 75090-0504, United States
  • US Oncology
    The Woodlands, Texas 77380, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Texas Oncology-Deke Slayton Cancer Center
    Webster, Texas 77598-4219, United States
  • Texas Oncology-Wichital Falls Texoma Cancer Center
    Wichita Falls, Texas 76310, United States
  • Intermountain Medical Center
    Saint George, Utah 84790, United States
  • Hematology Oncology Associates of Fredericksburg Inc.
    Fredericksburg, Virginia 22408, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Oncology and Hematology Associates of Southwest Virginia Inc
    Salem, Virginia 24153, United States
  • Shenandoah Oncology, P.C.
    Winchester, Virginia 22601, United States
  • Centro de Oncologia e Investigacion Buenos Aires
    Berazategui, Buenos Aires B1884BBF, Argentina
  • CEMEDIC
    Caba, Buenos Aires C1440CFD, Argentina
  • CENIT Centro de Neurociencias, Investigación y Tratamiento
    Caba, Ciudad Autonoma Buenos Aires C1125ABD, Argentina
  • Centro Medico San Roque
    San Miguel de Tucumán, Tucuman T4000IAK, Argentina
  • Clinica Adventista de Belgrano
    Ciudad Autonoma Buenos Aires, C1430EGF, Argentina
  • Sanatorio Parque
    Salta, 4400, Argentina
  • Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan
    San Juan, J5402DIL, Argentina
  • Centro para la Atencion Integral del Paciente Oncologico
    Tucumain, 4000, Argentina
  • Universitätsklinikum Graz
    Graz, Steiermark 8036, Austria
  • Universitätsklinik Innsbruck
    Innsbruck, Tirol 6020, Austria
  • Universitätsklinikum Salzburg
    Salzburg, 5020, Austria
  • AKH
    Wien, 1090, Austria
  • Algemeen Ziekenhuis St Jan Brugge
    Brugge, 8000, Belgium
  • Hopital De Jolimont
    Haine-St.- Paul, 7100, Belgium
  • VZW REgional Ziekenhuis Jan Yperman
    Ieper, 8900, Belgium
  • Clinique Saint Pierre Ottignies
    Ottignies, 1340, Belgium
  • Núcleo de Oncologia da Bahia
    Salvador, Bahia 41170, Brazil
  • Instituto de Cancer de Londrina
    Londrina, Parana 86015-520, Brazil
  • Hospital de Caridade Ijui
    Ijui, Rio Grande Do Sul 98700 000, Brazil
  • Hospital São Lucas - PUCRS - ONCOLOGY
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • Instituto COI de Pesquisa Educação e Gestão
    Rio de Janeiro, RJ 22793-080, Brazil
  • Hospital Bruno Born de Lajeado
    Lajeado, RS 95900-000, Brazil
  • Fundação PIO XII
    Barretos, Sao Paulo 14784700, Brazil
  • Hospital de Base Fac de Medicina de Sao Jose do Rio Preto
    Sao Jose Rio Preto, Sao Paulo 15090-000, Brazil
  • Faculdade de Medicina do ABC
    Santo Andre, SP 09060-020, Brazil
  • Hospital das Clinicas da FMRP
    Ribeirao Preto, São Paulo 14048-900, Brazil
  • INCA - Instituto Nacional Do Cancer
    Rio de Janeiro, 20231, Brazil
  • Fundacao Antonio Prudente-Hosp. do Cancer AC Camargo
    Sao Paulo, 01509-900, Brazil
  • Soc. Beneficente de Senhoras Hospital Sirio Libanes-Oncology
    São Paulo, 01246, Brazil
  • Clin. Pesq.e Centro Estudos Oncologia Ginecológica e Mamária
    São Paulo, 01317-000, Brazil

Showing the first 100 of 119 sites across 9 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · www.clinicalstudydatarequest.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2019; primary completion for Mar 2022, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2019
First posted
Jun 17, 2019
StartEst.
Sep 16, 2019
Primary completionEst.
Mar 23, 2022
CompletionEst.
Mar 23, 2023
Last update
Sep 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03988114
Responsible party
Sponsor
First posted
Jun 17, 2019
Start date
Sep 16, 2019 (estimated)
Primary completion
Mar 23, 2022 (estimated)
Completion
Mar 23, 2023 (estimated)
Last update
Sep 6, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion